Acadian Asset Management
CLRB icon

Acadian Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Acadian Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46K Buy
+16,577
New +$46.4K ﹤0.01% 1858

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management's CLRB Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 16,577 shares worth $46K. The stake represents ﹤0.01% of the portfolio and ranks #1858 among its holdings.

18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Acadian Asset Management held 16,577 shares of Cellectar Biosciences worth $46K as of Q2 2026.
  • Cellectar Biosciences was a new Acadian Asset Management position in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1858 holding.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.